Skip to main content
. 2022 Jun 3;40(28):3289–3300. doi: 10.1200/JCO.21.02506

FIG 2.

FIG 2.

Comparison of HRs for bevacizumab plus chemotherapy versus temsirolimus plus chemotherapy by TP53 mutational status, expression by IHC, or integrated sequencing/IHC analysis. Forest plots of (A) PFS and (B) OS. Also show are HR and 95% CI. Significantly improved HRs are indicated in red. GOF, gain of function; HR, hazard ratio; IHC, immunohistochemistry; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; sVUF, somatic variants of unknown function; WT, wild-type.